For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Brain-Derived Neurotropic Factor/TrkB Signaling in the Pathogenesis and Novel Pharmacotherapy of SchizophreniaPillai A.
Department of Psychiatry and Health Behavior, Medical College of Georgia and Medical Research Service Line, Veterans Affairs Medical Center, Augusta, Ga., USA Corresponding Author
Medical Research Service (242), Veterans Affairs Medical Center, 5B-102
1 Freedom Way
Augusta, GA 30904 (USA)
Tel. +1 706 733 0188, ext. 2480, Fax +1 706 823 3949, E-Mail firstname.lastname@example.org
The role of neurotropins, predominantly brain-derived neurotropic factor (BDNF), has been implicated in the pathophysiology as well as treatment outcome of schizophrenia. Both human and rodent studies indicate that the beneficial effects of antipsychotic drugs are mediated, at least in part, through BDNF and its receptor, TrkB. This review will discuss the available data on the levels of BDNF and TrkB in subjects with schizophrenia and in animals with and without conventional antipsychotics. The data concerning the impact of the antipsychotic drugs on BDNF/TrkB signaling will also be discussed. More importantly, this review will provide future perspective on BDNF/TrkB signaling as a novel molecular target to correct the pathogenesis and improve the long-term clinical outcome by treatments with conventional and adjunctive drugs.
© 2008 S. Karger AG, Basel